AstraZeneca (BUE:AZN) Beta: N/A (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:AZN AstraZeneca PLC BUE:AZN
79 GF Score
Price ARS66,700.00
GF Value ARS71,271.93
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-23), AstraZeneca's Beta is Not available.

AstraZeneca  (BUE:AZN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

AstraZeneca Beta Related Terms

AstraZeneca Beta Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Beta Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BUE:AZN
79GF Score
AstraZeneca PLC BUE:AZN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is AstraZeneca (BUE:AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of ARS66,700.00 is trading 6.4% below its estimated GF Value™ of ARS71,271.93. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for BUE:AZN:

  • Beta: N/A
  • GF Value™: ARS71,271.93 vs. price of ARS66,700.00 (6.4% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
79GF Score

Get the complete analysis for BUE:AZN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS66,700.00
Price
ARS71,271.93
GF Value